Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ALX ONCOLOGY HOLDINGS INCALXO · Entity 6040 | Director | June 11, 2021 | June 15, 2021 |
| Olema Pharmaceuticals, Inc.OLMA · Entity 613 | Director | June 18, 2026 | June 23, 2026 |
| Science 37 Holdings, Inc.LSAQ · Entity 15235 | Director | November 20, 2020 | November 20, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ALX ONCOLOGY HOLDINGS INC
Report date June 11, 2021 · Filed June 15, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $59.66 · Expires 2031-06-10 | Direct | 12,004 |
Reported balance
After 2021-06-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-06-11 · Grant · Acquired 12,004 · Balance 12,004 F1: Shares subject to the option vest in 12 equal monthly installments on the same day of the month as the grant date, or if earlier, the day immediately before the day of the next annual meeting of stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares subject to the option vest in 12 equal monthly installments on the same day of the month as the grant date, or if earlier, the day immediately before the day of the next annual meeting of stockholders.
Olema Pharmaceuticals, Inc.
Report date June 18, 2026 · Filed June 23, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.51 · Expires 2036-06-18 | Direct | 29,500 |
Reported balance
After 2026-06-18 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-18 · Grant · Acquired 29,500 · Balance 29,500 F1: The shares subject to the option vest in a series of 12 successive equal monthly installments measured from June 18, 2026, subject to the Reporting Person's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to the Reporting Person's continuous service through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option vest in a series of 12 successive equal monthly installments measured from June 18, 2026, subject to the Reporting Person's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to the Reporting Person's continuous service through such vesting date.
Science 37 Holdings, Inc.
Report date November 20, 2020 · Filed November 20, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 6,000 |
Reported balance
Holding disclosure · report date 2020-11-20 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 6,000 |
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Akero Therapeutics, Inc.
Report date December 09, 2025 · Filed December 09, 2025
Section 16 reporting ended · disclosed 2025-12-09. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2025-12-09 transaction · row 1
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 1 · 2025-12-09 · Disposition to issuer · Disposed 93,000 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 9, 2025, among the Issuer, Novo Nordisk A/S, a Danish aktieselskab ("Novo"), and NN Invest Sub, Inc ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer (the "Merger"), effective as of December 9, 2025 (such date and time, the "Effective Time"), with the Issuer surviving the Merger as a wholly owned subsidiary of Novo. At the Effective Time, each share of common stock of the Issuer ("Company Common Stock") reported in this Form 4 was cancelled and converted into the right to receive (i) cash in an amount equal to $54.00 (the "Closing Consideration") and (ii) one contractual contingent value right (a "CVR") representing the right to receive $6.00 in cash, if a specified milestone is achieved, pursuant to the CVR Agreement (as defined in the Merger Agreement) ((i) and (ii), together, the "Merger Consideration"). |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2025-12-09 transaction · row 3
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 3 · 2025-12-09 · Disposition to issuer · Disposed 9,398 · Balance 0 F3: Represents restricted stock units ("Company RSUs") granted to the Reporting Person. Each Company RSU represented a contingent right to receive one share of Company Common Stock upon vesting of the Company RSU. F4: Pursuant to the Merger Agreement, at the Effective Time, each Company RSU reported in this Form 4 was deemed fully vested and cancelled and was converted into the right of the Reporting Person to receive the Merger Consideration in respect of each such Company RSU. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 0 |
Reported balance
After 2025-12-09 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2025-12-09 · Disposition to issuer · Disposed 1,200,000 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 9, 2025, among the Issuer, Novo Nordisk A/S, a Danish aktieselskab ("Novo"), and NN Invest Sub, Inc ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer (the "Merger"), effective as of December 9, 2025 (such date and time, the "Effective Time"), with the Issuer surviving the Merger as a wholly owned subsidiary of Novo. At the Effective Time, each share of common stock of the Issuer ("Company Common Stock") reported in this Form 4 was cancelled and converted into the right to receive (i) cash in an amount equal to $54.00 (the "Closing Consideration") and (ii) one contractual contingent value right (a "CVR") representing the right to receive $6.00 in cash, if a specified milestone is achieved, pursuant to the CVR Agreement (as defined in the Merger Agreement) ((i) and (ii), together, the "Merger Consideration"). F2: The shares are held by Logos Global Master Fund LP ("Logos Master Fund") and Logos Opportunities Fund IV LP ("LOF IV"). Logos GP LLC ("Logos GP") is the general partner of Logos Master Fund and the Reporting Person is a managing member of Logos GP. Logos Opportunities IV GP LLC ("GP IV") is the general partner of LOF IV and the Reporting Person is a managing member of GP IV. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $50.83 · Expires 2033-06-23 | Direct | 0 |
Reported balance
After 2025-12-09 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2025-12-09 · Disposition to issuer · Disposed 15,000 · Balance 0 F5: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 9, 2025, among the Issuer, Novo Nordisk A/S, a Danish aktieselskab ("Novo"), and NN Invest Sub, Inc ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer (the "Merger"), effective as of December 9, 2025 (such date and time, the "Effective Time"), with the Issuer surviving the Merger as a wholly owned subsidiary of Novo. At the Effective Time, each share of common stock of the Issuer ("Company Common Stock") reported in this Form 4 was cancelled and converted into the right to receive (i) cash in an amount equal to $54.00 (the "Closing Consideration") and (ii) one contractual contingent value right (a "CVR") representing the right to receive $6.00 in cash, if a specified milestone is achieved, pursuant to the CVR Agreement (as defined in the Merger Agreement) ((i) and (ii), together, the "Merger Consideration").
F2: The shares are held by Logos Global Master Fund LP ("Logos Master Fund") and Logos Opportunities Fund IV LP ("LOF IV"). Logos GP LLC ("Logos GP") is the general partner of Logos Master Fund and the Reporting Person is a managing member of Logos GP. Logos Opportunities IV GP LLC ("GP IV") is the general partner of LOF IV and the Reporting Person is a managing member of GP IV. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.
F3: Represents restricted stock units ("Company RSUs") granted to the Reporting Person. Each Company RSU represented a contingent right to receive one share of Company Common Stock upon vesting of the Company RSU.
F4: Pursuant to the Merger Agreement, at the Effective Time, each Company RSU reported in this Form 4 was deemed fully vested and cancelled and was converted into the right of the Reporting Person to receive the Merger Consideration in respect of each such Company RSU.
F5: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 02, 2022 Filed Jun 3, 2022 16:06 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $8.13 | $0.00 |
DisclosureSEC source: 0000899243-22-020937 · doc4.xml · derivative · entry 1 Graham G. Walmsley · CIK 0001777517 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2032-06-01 F1 · derivative.exercise_date: This option shall vest in full upon the earlier of (i) June 2, 2023 or (ii) the date of the next annual meeting, all vesting shall cease if the director resigns from the Board or otherwise ceases to service as a director. Read SEC document |
| June 11, 2021 Filed Jun 15, 2021 23:03 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | GrantStock option (right to buy) · Derivative | 12,004 | $0.00 Strike: $59.66 | $0.00 |
DisclosureSEC source: 0001209191-21-040738 · doc4.xml · derivative · entry 1 Graham G. Walmsley · CIK 0001777517 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,004 Underlying: Common Stock · 12,004 shares Expires 2031-06-10 F1 · derivative.exercise_date: Shares subject to the option vest in 12 equal monthly installments on the same day of the month as the grant date, or if earlier, the day immediately before the day of the next annual meeting of stockholders. Read SEC document |
| June 09, 2021 Filed Jun 10, 2021 22:38 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | GrantStock Option (right to buy) · Derivative | 21,520 | $0.00 Strike: $27.66 | $0.00 |
DisclosureSEC source: 0001415889-21-002926 · form4-06102021_030659.xml · derivative · entry 1 Graham G. Walmsley · CIK 0001777517 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,520 Underlying: Common Stock · 21,520 shares Expires 2031-06-08 F1 · derivative.exercise_date: The shares subject to the option vest in a series of 12 successive equal monthly installments measured from June 9, 2021, subject to the Reporting Person's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to the Reporting Person's continuous service through such vesting date. Read SEC document |
| June 01, 2021 Filed Jun 3, 2021 17:55 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | GiftStock Option (Right to Buy) · Derivative | 13,000 | $0.00 Strike: $25.20 | $0.00 |
DisclosureSEC source: 0001104659-21-076496 · tm2118278-2_4seq1.xml · derivative · entry 6 Graham G. Walmsley · CIK 0001777517 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,000 shares Expires 2030-05-31 F2 · shares: On June 1, 2021, the reporting person transferred 13,000 options to an entity of which the reporting person is the sole member. F5 · derivative.exercise_date: This option is fully vested. Read SEC document |
| June 01, 2021 Filed Jun 3, 2021 17:55 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | GiftStock Option (Right to Buy) · Derivative | 23,832 | $0.00 Strike: $19.97 | $0.00 |
DisclosureSEC source: 0001104659-21-076496 · tm2118278-2_4seq1.xml · derivative · entry 4 Graham G. Walmsley · CIK 0001777517 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 23,832 shares Expires 2029-11-07 F3 · derivative.exercise_date: This option shall vest and become exercisable in 36 equal monthly installments, commencing on November 8, 2019. Read SEC document |
| June 01, 2021 Filed Jun 3, 2021 17:55 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | GiftStock Option (Right to Buy) · Derivative | 13,000 | $0.00 Strike: $26.32 | $0.00 |
DisclosureSEC source: 0001104659-21-076496 · tm2118278-2_4seq1.xml · derivative · entry 2 Graham G. Walmsley · CIK 0001777517 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,000 shares Expires 2031-05-31 F2 · shares: On June 1, 2021, the reporting person transferred 13,000 options to an entity of which the reporting person is the sole member. F1 · derivative.exercise_date: This option shall vest in full upon the earlier of (i) June 1, 2022 or (ii) the date of the next annual meeting, all vesting shall cease if the director resigns from the Board or otherwise ceases to service as a director. Read SEC document |
| June 01, 2021 Filed Jun 3, 2021 17:55 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | GrantStock Option (Right to Buy) · Derivative | 13,000 | $0.00 Strike: $26.32 | $0.00 |
DisclosureSEC source: 0001104659-21-076496 · tm2118278-2_4seq1.xml · derivative · entry 1 Graham G. Walmsley · CIK 0001777517 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,000 Underlying: Common Stock · 13,000 shares Expires 2031-05-31 F1 · derivative.exercise_date: This option shall vest in full upon the earlier of (i) June 1, 2022 or (ii) the date of the next annual meeting, all vesting shall cease if the director resigns from the Board or otherwise ceases to service as a director. Read SEC document |
| December 14, 2020 Filed Dec 16, 2020 00:07 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | PurchaseCommon Stock | 20,000 | $76.00 | $1,520,000.00 |
DisclosureSEC source: 0000899243-20-033928 · doc4.xml · nonDerivative · entry 1 Graham G. Walmsley · CIK 0001777517 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 995,000 F1 · ownership.nature: The shares are held of record by Logos Global Master Fund, L.P. (LGMF LP). As a managing member of Logos GP LLC, the general partner of LGMF LP, the reporting person shares voting and dispositive power with respect to the shares held of record by LGMF LP but disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein. Read SEC document |
| November 23, 2020 Filed Nov 23, 2020 21:35 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | ConversionSeries C Convertible Preferred Stock · Derivative | 1,183,114 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-059979 · doc4.xml · derivative · entry 5 Graham G. Walmsley · CIK 0001777517 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 1,183,114 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The shares of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock were convertible into Common Stock on a 1:1 basis and had no expiration date. Immediately upon the closing of the Issuer's initial public offering, all shares of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock automatically converted into shares of Common Stock. F1 · price: The shares of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock were convertible into Common Stock on a 1:1 basis and had no expiration date. Immediately upon the closing of the Issuer's initial public offering, all shares of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock automatically converted into shares of Common Stock. F1 · derivative.exercise_date: The shares of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock were convertible into Common Stock on a 1:1 basis and had no expiration date. Immediately upon the closing of the Issuer's initial public offering, all shares of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock automatically converted into shares of Common Stock. F1 · derivative.expiration_date: The shares of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock were convertible into Common Stock on a 1:1 basis and had no expiration date. Immediately upon the closing of the Issuer's initial public offering, all shares of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock automatically converted into shares of Common Stock. F3 · ownership.nature: The shares are held by Logos Opportunities Fund II, L.P. ("Logos Fund II"). Logos Opportunities GP is the general partner of Logos Fund II and the Reporting Person is a managing member of Logos Opportunities GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. Read SEC document |
| November 23, 2020 Filed Nov 23, 2020 21:35 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | ConversionSeries B Convertible Preferred Stock · Derivative | 1,400,761 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-059979 · doc4.xml · derivative · entry 4 Graham G. Walmsley · CIK 0001777517 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 1,400,761 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The shares of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock were convertible into Common Stock on a 1:1 basis and had no expiration date. Immediately upon the closing of the Issuer's initial public offering, all shares of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock automatically converted into shares of Common Stock. F1 · price: The shares of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock were convertible into Common Stock on a 1:1 basis and had no expiration date. Immediately upon the closing of the Issuer's initial public offering, all shares of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock automatically converted into shares of Common Stock. F1 · derivative.exercise_date: The shares of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock were convertible into Common Stock on a 1:1 basis and had no expiration date. Immediately upon the closing of the Issuer's initial public offering, all shares of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock automatically converted into shares of Common Stock. F1 · derivative.expiration_date: The shares of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock were convertible into Common Stock on a 1:1 basis and had no expiration date. Immediately upon the closing of the Issuer's initial public offering, all shares of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock automatically converted into shares of Common Stock. F2 · ownership.nature: The shares are held by Logos Opportunities Fund I L.P. ("Logos Fund I"). Logos Opportunities GP, LLC ("Logos Opportunities GP") is the general partner of Logos Fund I and the Reporting Person is a managing member of Logos Opportunities GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. Read SEC document |
| November 23, 2020 Filed Nov 23, 2020 21:35 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | PurchaseCommon Stock | 1,160,000 | $19.00 | $22,040,000.00 |
DisclosureSEC source: 0001209191-20-059979 · doc4.xml · nonDerivative · entry 3 Graham G. Walmsley · CIK 0001777517 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,160,000 F4 · ownership.nature: The shares are held by Logos Global Master Fund LP ("Logos Master Fund"). Logos GP LLC ("Logos GP") is the general partner of Logos Master Fund and the Reporting Person is a managing member of Logos GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. Read SEC document |
| November 23, 2020 Filed Nov 23, 2020 21:35 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | ConversionCommon Stock | 1,183,114 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-059979 · doc4.xml · nonDerivative · entry 2 Graham G. Walmsley · CIK 0001777517 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,183,114 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock were convertible into Common Stock on a 1:1 basis and had no expiration date. Immediately upon the closing of the Issuer's initial public offering, all shares of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock automatically converted into shares of Common Stock. F3 · ownership.nature: The shares are held by Logos Opportunities Fund II, L.P. ("Logos Fund II"). Logos Opportunities GP is the general partner of Logos Fund II and the Reporting Person is a managing member of Logos Opportunities GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. Read SEC document |
| November 23, 2020 Filed Nov 23, 2020 21:35 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | ConversionCommon Stock | 1,400,761 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-059979 · doc4.xml · nonDerivative · entry 1 Graham G. Walmsley · CIK 0001777517 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,400,761 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock were convertible into Common Stock on a 1:1 basis and had no expiration date. Immediately upon the closing of the Issuer's initial public offering, all shares of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock automatically converted into shares of Common Stock. F2 · ownership.nature: The shares are held by Logos Opportunities Fund I L.P. ("Logos Fund I"). Logos Opportunities GP, LLC ("Logos Opportunities GP") is the general partner of Logos Fund I and the Reporting Person is a managing member of Logos Opportunities GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. Read SEC document |
| November 18, 2020 Filed Nov 20, 2020 00:01 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | GrantStock Option (Right to Buy) · Derivative | 21,520 | $0.00 Strike: $19.00 | $0.00 |
DisclosureSEC source: 0001209191-20-059528 · doc4.xml · derivative · entry 5 Graham G. Walmsley · CIK 0001777517 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,520 Underlying: Common Stock · 21,520 shares Expires 2030-11-17 F5 · derivative.exercise_date: The shares subject to the option vest in a series of 36 successive equal monthy installments measured from November 18, 2020, subject to the Reporting Person's continuous service through each applicable vesting date. Read SEC document |
| November 18, 2020 Filed Nov 20, 2020 00:01 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | GrantStock Option (Right to Buy) · Derivative | 21,520 | $0.00 Strike: $19.00 | $0.00 |
DisclosureSEC source: 0001209191-20-059528 · doc4.xml · derivative · entry 4 Graham G. Walmsley · CIK 0001777517 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,520 Underlying: Common Stock · 21,520 shares Expires 2030-11-17 F5 · derivative.exercise_date: The shares subject to the option vest in a series of 36 successive equal monthy installments measured from November 18, 2020, subject to the Reporting Person's continuous service through each applicable vesting date. Read SEC document |
| November 18, 2020 Filed Nov 20, 2020 00:01 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | GrantStock Option (Right to Buy) · Derivative | 21,520 | $0.00 Strike: $19.00 | $0.00 |
DisclosureSEC source: 0001209191-20-059528 · doc4.xml · derivative · entry 3 Graham G. Walmsley · CIK 0001777517 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,520 Underlying: Common Stock · 21,520 shares Expires 2030-11-17 F4 · derivative.exercise_date: The shares subject to the option vest in a series of 12 successive equal monthy installments measured from June 1, 2020, subject to the Reporting Person's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to the Reporting Person's continuous service through such vesting date. Read SEC document |
| September 30, 2020 Filed Nov 20, 2020 00:01 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | PurchaseSeries C Convertible Preferred Stock · Derivative | 1,183,114 | $11.06 | $13,087,962.00 |
DisclosureSEC source: 0001209191-20-059528 · doc4.xml · derivative · entry 2 Graham G. Walmsley · CIK 0001777517 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,183,114 Underlying: Common Stock · 1,183,114 shares Expires not disclosed F1 · derivative.exercise_price: The shares of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock are convertible into Common Stock on a 1:1 basis and have no expiration date. Immediately upon the closing of the Issuer's initial public offering, all shares of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock will be automatically converted into shares of Common Stock. F1 · derivative.exercise_date: The shares of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock are convertible into Common Stock on a 1:1 basis and have no expiration date. Immediately upon the closing of the Issuer's initial public offering, all shares of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock will be automatically converted into shares of Common Stock. F1 · derivative.expiration_date: The shares of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock are convertible into Common Stock on a 1:1 basis and have no expiration date. Immediately upon the closing of the Issuer's initial public offering, all shares of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock will be automatically converted into shares of Common Stock. F3 · ownership.nature: The shares are held by Logos Opportunities Fund II, L.P. ("Logos Fund II"). Logos GP is the general partner of Logos Fund II and the Reporting Person is a managing member of Logos GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. Read SEC document |
| July 21, 2020 Filed Jul 22, 2020 00:04 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | ConversionSeries C Convertible Preferred Stock · Derivative | 2,105,901 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-019913 · doc4.xml · derivative · entry 3 Graham G. Walmsley · CIK 0001777517 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 2,105,901 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series C Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F1 · price: Each share of Series C Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F1 · derivative.exercise_date: Each share of Series C Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F1 · derivative.expiration_date: Each share of Series C Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F3 · ownership.nature: The shares are held of record by Logos Opportunities Fund I, L.P. (LOF I LP). As a managing member of Logos Opportunities GP, LLC, the general partner of LOF I LP, the reporting person shares voting and dispositive power with respect to the shares held of record by LOF I LP but disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein. Read SEC document |
| July 21, 2020 Filed Jul 22, 2020 00:04 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | PurchaseCommon Stock | 975,000 | $19.00 | $18,525,000.00 |
DisclosureSEC source: 0000899243-20-019913 · doc4.xml · nonDerivative · entry 2 Graham G. Walmsley · CIK 0001777517 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 975,000 F4 · ownership.nature: The shares are held of record by Logos Global Master Fund, L.P. (LGMF LP). As a managing member of Logos GP LLC, the general partner of LGMF LP, the reporting person shares voting and dispositive power with respect to the shares held of record by LGMF LP but disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein. Read SEC document |
| July 21, 2020 Filed Jul 22, 2020 00:04 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | ConversionCommon Stock | 2,105,901 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-019913 · doc4.xml · nonDerivative · entry 1 Graham G. Walmsley · CIK 0001777517 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,161,981 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series C Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F2 · balance_after: Includes 56,080 shares of Common Stock issued as payment of accrued dividends upon conversion of the preferred stock on July 21, 2020. F3 · ownership.nature: The shares are held of record by Logos Opportunities Fund I, L.P. (LOF I LP). As a managing member of Logos Opportunities GP, LLC, the general partner of LOF I LP, the reporting person shares voting and dispositive power with respect to the shares held of record by LOF I LP but disclaims beneficial ownership of such shares except to the extent of his individual pecuniary interest therein. Read SEC document |
| July 16, 2020 Filed Jul 17, 2020 23:10 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | GrantStock Option (right to buy) · Derivative | 24,009 | $0.00 Strike: $19.00 | $0.00 |
DisclosureSEC source: 0000899243-20-019581 · doc4.xml · derivative · entry 1 Graham G. Walmsley · CIK 0001777517 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,009 Underlying: Common Stock · 24,009 shares Expires 2030-07-16 F1 · derivative.exercise_date: Shares subject to the option vest in 36 equal monthly installments beginning on August 16, 2020. Read SEC document |
| June 01, 2020 Filed Jun 2, 2020 18:53 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | GrantStock Option (Right to Buy) · Derivative | 13,000 | $0.00 Strike: $25.20 | $0.00 |
DisclosureSEC source: 0001104659-20-069072 · a4.xml · derivative · entry 1 Graham G. Walmsley · CIK 0001777517 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,000 Underlying: Common Stock · 13,000 shares Expires 2030-05-31 F1 · derivative.exercise_date: This option shall vest in full upon the earlier of the first anniversary of the date of grant or the date of the next annual meeting, all vesting shall cease if the director resigns from the Board or otherwise ceases to service as a director. Read SEC document |
| June 01, 2020 Filed Nov 20, 2020 00:01 UTC | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | PurchaseSeries B Convertible Preferred Stock · Derivative | 339,578 | $4.71 | $1,599,989.66 |
DisclosureSEC source: 0001209191-20-059528 · doc4.xml · derivative · entry 1 Graham G. Walmsley · CIK 0001777517 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 339,578 Underlying: Common Stock · 339,578 shares Expires not disclosed F1 · derivative.exercise_price: The shares of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock are convertible into Common Stock on a 1:1 basis and have no expiration date. Immediately upon the closing of the Issuer's initial public offering, all shares of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock will be automatically converted into shares of Common Stock. F1 · derivative.exercise_date: The shares of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock are convertible into Common Stock on a 1:1 basis and have no expiration date. Immediately upon the closing of the Issuer's initial public offering, all shares of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock will be automatically converted into shares of Common Stock. F1 · derivative.expiration_date: The shares of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock are convertible into Common Stock on a 1:1 basis and have no expiration date. Immediately upon the closing of the Issuer's initial public offering, all shares of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock will be automatically converted into shares of Common Stock. F2 · ownership.nature: The shares are held by Logos Opportunities Fund I L.P. ("Logos Fund I"). Logos Opportunies GP, LLC ("Logos GP") is the general partner of Logos Fund I and the Reporting Person is a managing member of Logos GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. Read SEC document |
| June 01, 2020 Filed Nov 20, 2020 23:43 UTC Amendment | Olema Pharmaceuticals, Inc. OLMA · Entity 613 | PurchaseSeries B Convertible Preferred Stock · Derivative | 339,578 | $4.71 | $1,599,989.66 |
DisclosureSEC source: 0001209191-20-059760 · doc4a.xml · derivative · entry 1 Graham G. Walmsley · CIK 0001777517 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,400,761 Underlying: Common Stock · 339,578 shares Expires not disclosed F1 · derivative.exercise_price: The shares of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock are convertible into Common Stock on a 1:1 basis and have no expiration date. Immediately upon the closing of the Issuer's initial public offering, all shares of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock will be automatically converted into shares of Common Stock. F1 · derivative.exercise_date: The shares of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock are convertible into Common Stock on a 1:1 basis and have no expiration date. Immediately upon the closing of the Issuer's initial public offering, all shares of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock will be automatically converted into shares of Common Stock. F1 · derivative.expiration_date: The shares of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock are convertible into Common Stock on a 1:1 basis and have no expiration date. Immediately upon the closing of the Issuer's initial public offering, all shares of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock will be automatically converted into shares of Common Stock. F2 · ownership.nature: The shares are held by Logos Opportunities Fund I L.P. ("Logos Fund I"). Logos Opportunities GP, LLC ("Logos GP") is the general partner of Logos Fund I and the Reporting Person is a managing member of Logos GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. Read SEC document |
| March 30, 2020 Filed Apr 1, 2020 18:52 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | Exercise / conversionCommon Stock | 2,168 | $19.97 | $43,294.96 |
DisclosureSEC source: 0001104659-20-042006 · a4.xml · nonDerivative · entry 1 Graham G. Walmsley · CIK 0001777517 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,168 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 08, 2019 Filed Nov 12, 2019 19:02 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | GrantStock Option (Right to Buy) · Derivative | 26,000 | $0.00 Strike: $19.97 | $0.00 |
DisclosureSEC source: 0001104659-19-062783 · a4.xml · derivative · entry 1 Graham G. Walmsley · CIK 0001777517 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,000 Underlying: Common Stock · 26,000 shares Expires 2029-11-07 F1 · derivative.exercise_date: This option shall vest and become exercisable in 36 equal monthly installments, commencing on November 8, 2019. Read SEC document |
| November 08, 2019 Filed Apr 1, 2020 18:52 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,168 | $0.00 Strike: $19.97 | $0.00 |
DisclosureSEC source: 0001104659-20-042006 · a4.xml · derivative · entry 2 Graham G. Walmsley · CIK 0001777517 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,832 Underlying: Common Stock · 2,168 shares Expires 2029-11-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This option shall vest and become exercisable in 36 equal monthly installments, commencing on November 8, 2019. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.